Adolescent Care

Gynecomastia in adolescent males

Clinical Overview and When to Suspect

Gynecomastia is benign, glandular breast tissue enlargement in males — distinct from lipomastia (fat deposition without glandular proliferation)

Physiologic (pubertal) gynecomastia occurs in up to 50–70% of adolescent males, typically appearing at Tanner stage 2–3 (ages 10–14)

Pathophysiology: transient ↑ estrogen-to-androgen ratio during early puberty — estradiol rises before testosterone reaches adult levels; breast glandular tissue is stimulated before androgens predominate

Usually presents as a subareolar, often tender, rubbery disc — unilateral or bilateral (bilateral more common)

Board pearl: Physiologic pubertal gynecomastia is the MOST common cause of breast enlargement in adolescent males and is self-limited in ~90% of cases within 1–3 years

When to suspect pathology: onset before age 10 or after age 17, rapid progression, diameter >4 cm, associated virilization or feminization signs, galactorrhea, or failure to resolve by late adolescence

History — Key Questions and Risk Stratification

→ Spironolactone, ketoconazole, cimetidine, marijuana, anabolic steroids, risperidone, metoclopramide

→ Lavender and tea tree oil (environmental estrogen mimics)

Age of onset and pubertal timing: correlate with Tanner staging — physiologic gynecomastia peaks mid-puberty

Duration and trajectory: stable or slowly growing over months → likely physiologic; rapid enlargement → consider pathologic causes

Pain or tenderness: common in physiologic gynecomastia due to active glandular proliferation; absence does not exclude pathology

Medication and substance review — common culprits:

Chronic disease screen: liver disease (↓ SHBG metabolism → ↑ free estrogen), renal failure, hyperthyroidism

Family history: Klinefelter syndrome, aromatase excess syndrome

Clinical tip: Always ask about testicular symptoms — painless testicular mass may indicate hCG-secreting germ cell tumor causing gynecomastia

Physical Exam — Distinguishing True Gynecomastia from Mimics

→ True gynecomastia: firm, concentric, rubbery disc directly beneath areola

→ Lipomastia (pseudogynecomastia): soft, non-discrete adipose tissue; no glandular disc — common in obese adolescents

→ Small, firm testes → Klinefelter syndrome (47,XXY)

→ Asymmetric testicular mass → germ cell tumor

→ Normal testicular volume for Tanner stage → reassuring

Palpation technique: patient supine, examiner pinches breast between thumb and forefinger

Measure disc diameter: <4 cm and Tanner 2–4 → likely physiologic; ≥4 cm (macromastia) → less likely to resolve spontaneously

Examine testes bilaterally:

Assess Tanner staging of pubic hair and genitalia to confirm appropriate pubertal progression

Check for hepatomegaly (liver disease), thyromegaly (hyperthyroidism), and signs of adrenal pathology (striae, central obesity)

Board pearl: A hard, fixed, eccentric, or ulcerated breast mass in an adolescent male raises concern for breast malignancy (rare but testable) — refer for imaging and biopsy

Diagnostic Workup — When Labs Are and Are Not Needed

→ Prepubertal onset

→ Rapid growth or >4 cm

→ Delayed or absent puberty

→ Testicular mass or asymmetry

→ Signs of systemic disease

→ Persistence beyond age 17

→ Serum testosterone (total and free), estradiol, LH, FSH

→ β-hCG (screens for hCG-secreting tumors)

→ DHEA-S (adrenal androgen excess)

→ Prolactin (if galactorrhea)

→ Liver and thyroid function tests

Physiologic gynecomastia in a healthy pubertal male (Tanner 2–4, <4 cm, no red flags) requires NO laboratory evaluation — clinical diagnosis

Indications for workup:

First-line labs when workup is indicated:

Board pearl: ↑ LH/FSH with ↓ testosterone → primary hypogonadism (think Klinefelter); ↓ LH/FSH with ↓ testosterone → secondary hypogonadism (pituitary/hypothalamic)

Karyotype: obtain if clinical suspicion for Klinefelter (tall stature, small firm testes, learning difficulties, gynecomastia)

Imaging and Further Diagnostic Steps

→ Gynecomastia appears as hypoechoic, fan-shaped retroareolar tissue

→ Malignancy: irregular, eccentric, often with microcalcifications

Breast ultrasound: useful to confirm glandular tissue vs fat when exam is equivocal, or to evaluate a suspicious discrete mass

Testicular ultrasound: indicated when physical exam reveals asymmetry, mass, or ↑ β-hCG to evaluate for germ cell tumor (seminoma, Leydig cell tumor)

MRI of pituitary: consider if secondary hypogonadism identified (↓ LH/FSH, ↓ testosterone) to rule out prolactinoma or other sellar mass

Bone age: may be advanced in aromatase excess syndrome or estrogen-secreting tumors; can help assess remaining growth in decisions about surgical timing

Clinical tip: Imaging is NOT part of the routine evaluation for typical pubertal gynecomastia — it is reserved for atypical features or concerning lab findings

Management — Reassurance and Watchful Waiting

→ Educate teen and family: this is a normal part of puberty, occurs in the majority of boys, and resolves spontaneously in ~90% within 1–3 years

The cornerstone of physiologic gynecomastia management is reassurance and observation

Address psychological impact early: gynecomastia can cause significant embarrassment, social withdrawal, avoidance of activities (swimming, gym class), and depression

Clinical tip: Use motivational interviewing techniques to explore the teen's concerns — "On a scale of 1–10, how much does this bother you?" — validate distress without pathologizing

Schedule follow-up every 6 months to document trajectory and provide ongoing support

If the patient is overweight/obese: weight loss may reduce the lipomastia component and improve cosmetic appearance, though it does not eliminate true glandular tissue

Discontinue offending medications or substances when identified (marijuana, lavender oil, etc.)

Management — Pharmacologic Options

→ Tamoxifen (off-label): most studied; can ↓ breast tissue size and pain

→ Raloxifene: less studied in adolescents

Pharmacotherapy is rarely indicated and is NOT first-line for typical physiologic gynecomastia

Consider medical therapy only when: glandular tissue >4 cm, significant tenderness, persistence >2 years, or severe psychosocial distress AND tissue is still in the proliferative (non-fibrotic) phase

Selective estrogen receptor modulators (SERMs):

Aromatase inhibitors (e.g., anastrozole, letrozole): block conversion of androgens → estrogens; less consistent evidence in established gynecomastia; may impair bone density with prolonged use

Board pearl: Medical therapy is most effective in EARLY, active gynecomastia (<12 months); once fibrosis occurs, tissue becomes resistant to pharmacologic regression

Testosterone therapy is NOT indicated unless documented hypogonadism is present — exogenous testosterone can paradoxically worsen gynecomastia via aromatization to estradiol

Management — Surgical Referral and Subspecialty Involvement

→ Gynecomastia persists >2 years and glandular tissue has fibrosed

→ Macromastia (>4 cm) unlikely to regress

→ Severe psychosocial impact despite counseling

→ Failed medical therapy

→ Workup suggests Klinefelter, aromatase excess, estrogen-secreting tumor, or hypogonadism

→ Prepubertal gynecomastia of any size

→ Significant body image disturbance, school avoidance, or depression related to gynecomastia

Surgical excision (subcutaneous mastectomy ± liposuction) is the definitive treatment when:

Best to defer surgery until breast growth has plateaued and pubertal development is near-complete (Tanner 4–5) to minimize recurrence

Refer to pediatric endocrinology when:

Refer to adolescent medicine or psychology/psychiatry if:

Clinical tip: Document the psychosocial impact thoroughly — insurance coverage for surgery often requires evidence of functional impairment

Age-Specific Considerations — Neonatal and Prepubertal

→ Common and transient — caused by maternal/placental estrogen exposure in utero

→ Breast buds palpable in both sexes at birth; may persist weeks to months

→ "Witch's milk" (galactorrhea) can occur — benign, self-limited; do NOT squeeze or express

→ Resolves spontaneously; no workup needed

→ UNCOMMON and warrants investigation

→ Differential: exogenous estrogen exposure (lavender/tea tree oil, maternal creams, contaminated foods), estrogen-secreting tumor (adrenal or testicular), aromatase excess syndrome, McCune-Albright syndrome

→ Workup: estradiol, testosterone, LH, FSH, DHEA-S, β-hCG; consider adrenal/testicular imaging

Neonatal gynecomastia:

Prepubertal gynecomastia (ages 2–9):

Board pearl: Gynecomastia in a prepubertal boy is NEVER considered physiologic — always evaluate for an underlying cause

Age-Specific Considerations — Pubertal and Late Adolescent

→ Peak incidence at age 13–14, coinciding with mid-puberty

→ Usually bilateral but may be asymmetric; tenderness is common during active proliferation

→ Most resolves within 6–18 months; vast majority by 2–3 years

→ Observation is appropriate if Tanner staging, growth velocity, and testicular volume are normal

→ Persistent gynecomastia (>2 years, Tanner 5) has likely undergone fibrosis → medical therapy less effective

→ Re-evaluate for pathologic causes if not previously done

→ Consider surgical referral for persistent, bothersome tissue

→ Address psychosocial burden — college, relationships, locker rooms

Pubertal (Tanner 2–4, ages ~10–15):

Late adolescent (ages 16–21):

Board pearl: New-onset gynecomastia AFTER pubertal completion is not physiologic and should prompt evaluation for drug/substance use, hepatic disease, hyperthyroidism, hypogonadism, or tumor

Transition: ensure adolescent understands the benign nature and self-advocacy strategies as they move to adult care

Complications — Psychosocial and Physical

→ Embarrassment, teasing/bullying, school avoidance, social withdrawal

→ Avoidance of sports and physical activity → secondary weight gain

→ Depressive symptoms, anxiety, body dysmorphic features

→ ↓ self-esteem during a critical period of identity formation

→ Breast tenderness limiting activity

→ Skin maceration or intertrigo under large breast tissue

→ Exceedingly rare: male breast cancer — risk is ↑ in Klinefelter syndrome but remains very low in adolescence

The primary "complication" of adolescent gynecomastia is psychosocial distress:

Board pearl: The degree of psychosocial distress does NOT correlate linearly with breast size — even mild gynecomastia can be devastating to some teens

Physical complications are rare:

Post-surgical complications (if surgery pursued): hematoma, seroma, asymmetry, scar contracture, nipple hypesthesia, recurrence if performed before pubertal completion

When to Escalate Care or Hospitalize

→ Testicular mass palpated or ↑ β-hCG → suspect germ cell tumor → urgent testicular ultrasound and oncology referral

→ Signs of adrenal mass (virilization + feminization, abdominal mass, ↑ DHEA-S + ↑ estradiol) → imaging and endocrine/oncology referral

→ Acute suicidal ideation related to body image distress → mental health crisis intervention

→ Klinefelter phenotype identified → endocrinology for testosterone replacement, fertility counseling, and associated comorbidity screening (metabolic syndrome, osteoporosis, learning disabilities)

→ Persistent macromastia causing functional impairment → plastic surgery referral

Hospitalization is almost never required for gynecomastia itself

Escalate urgently when:

Escalate non-urgently when:

Clinical tip: Always screen for suicidality when an adolescent male expresses significant distress about gynecomastia — do not assume it is "just cosmetic"

Key Differentials — Lipomastia and Pathologic Causes

→ Most common mimic; soft adipose tissue without firm glandular disc

→ Associated with obesity; improves with weight loss

→ Differentiated by palpation technique (no retroareolar disc) and, if needed, ultrasound

→ Mechanism varies: anti-androgens (spironolactone, ketoconazole), ↑ prolactin (risperidone, metoclopramide), direct estrogen effect (marijuana, anabolic steroids)

→ Reversible with drug discontinuation if caught before fibrosis

→ 1 in 500–600 males; most common sex chromosome aneuploidy

→ Features: tall stature, small firm testes, ↓ testosterone, ↑ LH/FSH, learning/behavioral difficulties, gynecomastia

→ Board pearl: Klinefelter is the most common pathologic cause of persistent gynecomastia in adolescent males

Lipomastia (pseudogynecomastia):

Drug-induced gynecomastia:

Klinefelter syndrome (47,XXY):

Estrogen-secreting tumors (Leydig cell, adrenal, hCG-secreting germ cell) → rare but must not be missed

Distinguishing Features in the Pediatric Population

→ Physiologic: Tanner 2–4, age 10–15, <4 cm, bilateral/symmetric, no testicular abnormality, no systemic signs → observe

→ Pathologic clues: prepubertal onset, postpubertal new onset, >4 cm, rapid growth, hard/eccentric mass, testicular mass, galactorrhea, virilization/feminization, failure to progress through puberty normally

→ Gynecomastia: central, bilateral (usually), soft-to-firm, mobile, symmetric around nipple

→ Malignancy: unilateral, hard, fixed, eccentric to nipple, skin/nipple changes, lymphadenopathy — exceedingly rare in teens but tested

→ ↑ SHBG → ↑ estrogen-to-androgen ratio → gynecomastia

→ Look for tachycardia, weight loss, tremor, goiter, exophthalmos

Physiologic vs pathologic — practical approach:

Gynecomastia vs breast cancer:

Hyperthyroidism:

Key distinction: Prolactinoma causes galactorrhea ± gynecomastia but is associated with ↓ testosterone and delayed puberty — check prolactin if galactorrhea present

Preventive Care and Screening Schedules

→ "Many boys notice some breast swelling during puberty — this is normal and almost always goes away on its own"

→ Proactively mentioning this can ↓ anxiety and ↑ likelihood the teen will raise concerns later

Universal screening: Bright Futures recommends annual well visits throughout adolescence — Tanner staging and breast exam should be part of every male adolescent physical

There is no formal population-based "screening" for gynecomastia — it is identified during routine pubertal assessment

Anticipatory guidance at Tanner 2:

Substance use prevention: counsel against marijuana and anabolic steroid use — both contribute to gynecomastia (and have numerous other risks)

Environmental exposure counseling: lavender and tea tree oil-containing products (shampoos, lotions) have estrogenic and anti-androgenic activity

Board pearl: Proactive normalization of pubertal gynecomastia at routine well visits is a high-yield anticipatory guidance point on boards

Follow-Up Strategy and Monitoring

→ Reassess every 6 months — document breast tissue diameter and Tanner stage

→ Track pubertal progression: if puberty stalls or regresses, re-evaluate

→ Most cases resolve within 1–2 years; if persisting >2 years or >4 cm, reassess etiology and consider intervention

→ Recheck 3–6 months after discontinuing offending agent — glandular tissue may regress if caught early

→ Follow-up per subspecialty recommendations (endocrinology, oncology)

→ Klinefelter: lifelong follow-up for testosterone replacement, fertility, bone density, metabolic syndrome

For physiologic gynecomastia:

For drug-induced gynecomastia:

For pathologic causes:

Clinical tip: At each follow-up, reassess psychosocial impact — even if tissue is resolving, the teen may still be struggling

Document response to any pharmacotherapy: measure breast diameter and pain scale at each visit

Family Counseling and Psychosocial Considerations

→ Gynecomastia during puberty is normal, common, and almost always self-limited

→ It does NOT indicate feminization, low masculinity, or gender change

→ It does NOT predict future breast cancer risk (unless Klinefelter)

Begin by addressing the teen's and parent's emotional response — gynecomastia often causes parental anxiety ("Is it cancer?") and teen embarrassment

Key counseling points:

Validate the teen's distress: "I hear that this is really bothering you — that's completely understandable, and we're going to work on this together"

Clinical tip: Use motivational interviewing to assess readiness for intervention and explore what bothers the teen most — appearance? pain? teasing?

Practical tips for coping: compression undershirts, loose-fitting clothing, staying physically active

Discuss timeline expectations honestly: "This will likely take 6–18 months to improve. Let's check every 6 months and see how things are going."

Screen for depression (PHQ-A), bullying, and body image concerns at each visit

If considering surgery: involve adolescent fully in decision-making, discuss realistic cosmetic outcomes and risks

High-Yield Associations and Rapid-Fire Facts

50–70% of pubertal males affected → most common breast condition in adolescent males

Peak incidence: age 13–14 (Tanner 2–3)

Resolves spontaneously in ~90% within 1–3 years

Klinefelter (47,XXY) → #1 pathologic cause of persistent gynecomastia in adolescent males

Marijuana → ↑ gynecomastia risk (estrogenic activity)

Lavender/tea tree oil → environmental endocrine disruptors → prepubertal gynecomastia

Spironolactone → anti-androgen → gynecomastia (common board trigger)

↑ β-hCG + gynecomastia → think germ cell tumor → urgent testicular ultrasound

Tamoxifen (SERM) → most studied pharmacotherapy for persistent symptomatic gynecomastia (off-label)

Exogenous testosterone does NOT treat gynecomastia and may worsen it via aromatization

Fibrotic tissue (>12 months) → resistant to medical therapy → surgery is definitive

Board pearl: Prepubertal gynecomastia = always pathologic; pubertal gynecomastia = almost always physiologic

One-Line Recap

Physiologic pubertal gynecomastia affects 50–70% of adolescent males at Tanner 2–3 (peak age 13–14), presents as a tender subareolar glandular disc, results from a transient ↑ estrogen-to-androgen ratio, resolves spontaneously in ~90% within 1–3 years, requires NO workup if pubertal progression is normal and tissue is <4 cm — but prepubertal onset, rapid enlargement, >4 cm, testicular abnormality, or persistence beyond 2 years demands evaluation (testosterone, estradiol, LH/FSH, β-hCG, karyotype if Klinefelter suspected), with Klinefelter syndrome being the #1 pathologic cause; management prioritizes reassurance, psychosocial support, substance avoidance (marijuana, lavender/tea tree oil), medication review, tamoxifen for refractory proliferative-phase disease, and surgical excision for fibrosed persistent macromastia — always screening for the psychosocial impact that drives most of the morbidity.

Board Question Stem Patterns

13-year-old Tanner 3 male with bilateral tender subareolar breast buds, otherwise healthy → diagnosis: physiologic gynecomastia → next step: reassurance and observation

14-year-old with gynecomastia + small firm testes + tall stature + learning difficulties → suspect Klinefelter → next step: karyotype

15-year-old with rapidly enlarging unilateral breast tissue + hard testicular mass → suspect germ cell tumor → next step: β-hCG, testicular ultrasound

Obese 12-year-old male with soft bilateral chest fullness, no glandular disc on exam → lipomastia → next step: diet/exercise counseling, no labs

16-year-old on risperidone develops bilateral breast tenderness and enlargement → drug-induced gynecomastia → next step: consider medication change in consultation with psychiatry

8-year-old prepubertal boy with bilateral breast buds, uses lavender shampoo → exogenous estrogen exposure → next step: discontinue product, monitor

17-year-old with persistent gynecomastia >2 years, Tanner 5, fibrotic tissue → medical therapy unlikely effective → next step: surgical referral

Board pearl: Vignettes with normal pubertal timing + small bilateral gynecomastia → answer is reassurance; any atypical feature → answer is workup

Previous Item

Next Item

eduo

visual

Adolescent Care

eduovisual

Products

Exams

Company